Optimi Health Corp. (TSE:OPTI) has released an update.
Optimi Health Corp., a notable player in the psychedelics pharmaceutical industry, has been announced as the Presenting Sponsor for the upcoming 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston. During this event, Optimi’s CEO, Bill Ciprick, will speak on the advancement of GMP psychedelic manufacturing, highlighting the company’s expertise and commitment to quality and safety in drug production. The conference will provide a platform for Optimi to engage with industry leaders and showcase its contributions to psychedelic therapeutics, including its recent collaboration with Mind Medicine Australia and an agreement to supply research-grade MDMA to the Institute for Psychedelic Research at Tel Aviv University.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
